Publications by authors named "McNancy Kang"
Article Synopsis
- The study explored the use of panobinostat, a histone deacetylase (HDAC) inhibitor, in combination with standard chemotherapy to enhance treatment effectiveness in older patients with acute myeloid leukemia (AML).
- In the trial, 25 patients (ages 60-85) received panobinostat alongside chemotherapy drugs daunorubicin and cytarabine, with results showing a 32% rate of complete response or incomplete count recovery (CR/CRi) and a median overall survival of 10 months.
- The findings indicated that panobinostat was well tolerated and significantly increased histone acetylation in patients, which was associated with better treatment outcomes, leading to a recommendation for future studies to use
Autoimmune diabetes mellitus (DM) results from the destruction of pancreatic islet cells by activated T lymphocytes, which have been primed by activated dendritic cells (DC). Individualized therapy with ex vivo DC manipulation and reinfusion has been proposed as a treatment for DM, but this treatment is limited by cost, and requires specialized facilities. A means of in situ modulation of the DC phenotype in the host would be more accessible.
View Article and Find Full Text PDFBackground: The Toll-like receptor 7 (TLR7) activator imiquimod (IMQ) is safe and effective in treating actinic keratosis; however, an intermittent treatment regimen is necessary because of excessive local reactions.
Objectives: To evaluate in vitro potency, pharmacodynamics/pharmacokinetics, toxicity and efficacy in vivo of the newly developed TLR7 ligand-phospholipid conjugate, TMX-202, in a gel formulation.
Material And Methods: The effects of TMX-202 were assessed both in vitro on a murine macrophage cell line and in primary bone marrow-derived dendritic cells and in vivo on mice (C57BL/6-wild type, Myd88(-/-) and Tlr7(-/-)).